Translational Imaging in Cerebral Tumors.

IF 10 1区医学 Q1 ONCOLOGY Clinical Cancer Research Pub Date : 2024-11-01 DOI:10.1158/1078-0432.CCR-24-2013

Alexey Surov, Jan Borggrefe

引用次数: 0

Abstract

Despite emerging possibilities of molecular histopathologic characterization, multiparametric MRI plays a key role in the diagnosis and classification of cerebral tumors. Imaging may also provide additional information about relevant histopathologic features of these tumors. See related article by Gao et al., p. 4876.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

脑肿瘤的转化成像。

尽管分子组织病理学特征描述的可能性不断增加，但多参数磁共振成像（MTP）在脑肿瘤的诊断和分类中仍发挥着关键作用。成像还能提供这些肿瘤相关组织病理学特征的更多信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical Cancer Research 医学-肿瘤学

CiteScore

20.10

自引率

1.70%

发文量

1207

审稿时长

2.1 months

期刊介绍： Clinical Cancer Research is a journal focusing on groundbreaking research in cancer, specifically in the areas where the laboratory and the clinic intersect. Our primary interest lies in clinical trials that investigate novel treatments, accompanied by research on pharmacology, molecular alterations, and biomarkers that can predict response or resistance to these treatments. Furthermore, we prioritize laboratory and animal studies that explore new drugs and targeted agents with the potential to advance to clinical trials. We also encourage research on targetable mechanisms of cancer development, progression, and metastasis.

期刊最新文献

Anti-tumor activity and biomarker analysis for TROP2-antibody drug conjugate Datopotamab deruxtecan in patient-derived breast cancer xenograft models. Response-Adaptive Surgical Timing in neoadjuvant immunotherapy demonstrates enhanced pathologic treatment response in Head and Neck Squamous Cell Carcinoma. A phase II open label, randomized clinical trial of atezolizumab with or without human recombinant IL-7 (CYT107) in advanced urothelial cancer. Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death. Phase Ib pharmacodynamic study of the MNK inhibitor Tomivosertib (eFT508) combined with paclitaxel in patients with refractory metastatic breast cancer.